NasdaqGS - Delayed Quote • USD
Guardant Health, Inc. (GH)
At close: 4:00 PM EDT
After hours: 6:39 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 18 | 21 | 21 |
| Avg. Estimate | -0.85 | -0.81 | -3.21 | -2.91 |
| Low Estimate | -1.04 | -0.99 | -3.81 | -3.48 |
| High Estimate | -0.66 | -0.63 | -2.5 | -1.85 |
| Year Ago EPS | -1.3 | -0.67 | -4.28 | -3.21 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 18 | 22 | 22 |
| Avg. Estimate | 150.67M | 160.9M | 664.02M | 805.9M |
| Low Estimate | 147.6M | 157.2M | 658.6M | 753M |
| High Estimate | 161.9M | 166.54M | 678M | 869.9M |
| Year Ago Sales | 128.71M | 137.15M | 563.95M | 664.02M |
| Sales Growth (year/est) | 17.10% | 17.30% | 17.70% | 21.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.3 | -1.17 | -0.94 | -0.86 |
| EPS Actual | -1.3 | -0.67 | -0.73 | -1.58 |
| Difference | 0 | 0.5 | 0.21 | -0.72 |
| Surprise % | 0.00% | 42.70% | 22.30% | -83.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.85 | -0.81 | -3.21 | -2.91 |
| 7 Days Ago | -0.85 | -0.81 | -3.21 | -2.91 |
| 30 Days Ago | -0.84 | -0.8 | -3.16 | -2.86 |
| 60 Days Ago | -0.83 | -0.8 | -3.15 | -2.89 |
| 90 Days Ago | -0.87 | -0.84 | -3.35 | -3.01 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 1 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 34.60% | -- | -- | 8.60% |
| Next Qtr. | -20.90% | -- | -- | 11.90% |
| Current Year | 25.00% | -- | -- | 5.60% |
| Next Year | 9.30% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 27.80% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 4/29/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 4/15/2024 |
| Reiterates | Guggenheim: Neutral | 4/5/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/26/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/23/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 2/23/2024 |
Related Tickers
EXAS Exact Sciences Corporation
54.15
-8.96%
NTRA Natera, Inc.
95.55
-0.11%
ILMN Illumina, Inc.
111.35
+0.66%
TWST Twist Bioscience Corporation
43.20
+4.35%
CDNA CareDx, Inc
11.06
+8.64%
MYGN Myriad Genetics, Inc.
25.25
+5.43%
PSNL Personalis, Inc.
1.6500
+5.43%
FLGT Fulgent Genetics, Inc.
21.79
+2.44%
VCYT Veracyte, Inc.
20.63
+2.53%
NEO NeoGenomics, Inc.
15.50
+2.45%